We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Leica Biosystems Acquires Kreatech Diagnostics

By LabMedica International staff writers
Posted on 12 Aug 2013
Leica Biosystems (Newcastle-upon-Tyne, UK) announced that it has acquired Kreatech Diagnostics (Amsterdam, NL), a privately held provider of DNA fluorescent in situ hybridization (FISH) probes and target labeling reagents for microarrays.

Leica Biosystems is a leader in workflow solutions and automation, striving to advance cancer diagnostics. More...
The company provides anatomical pathology laboratories and researchers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. Leica’s easy-to-use offerings help improve workflow efficiency and diagnostic confidence.

Kreatech is a molecular diagnostics company focusing on the development and commercialization of innovative detection products. Its product portfolio enables customers to detect genetic aberrations that may lead to cancer or other diseases. Kreatech offers a broad commercial portfolio of repeat-free DNA-FISH probes and a dedicated portfolio for microarray labeling applications using its proprietary nonenzymatic Universal Linkage System (ULS) labeling technology.

Leica Biosystems’ Advanced Staining Business Unit based in Newcastle-upon-Tyne, UK will be joined by Kreatech. The combined business will develop targeted biomarker menus for Leica’s instrument platforms. Leica Biosystems provides the ThermoBrite, and BOND systems that are widely used to label tissue specimens for diagnostic interpretation in cytogenetics and pathology laboratories globally.

“We are very pleased with the acquisition of Kreatech, its extensive portfolio, and development expertise. This will allow Leica Biosystems to better serve our cytogenetics and anatomic pathology customers. It will also enable us to actively support the future development of personalized medicine by research and drug development companies,” said Matthias G. Weber, MD, President of Leica Biosystems. “By standardizing and supporting the interpretation of results with our Aperio ePathology imaging solutions, we will provide our customers with the ability to effectively and efficiently manage ever more complex diagnostic requirements.”

“Leica Biosystems is a very natural fit to take Kreatech to the next stage,” commented Kees Moonen, CEO of Kreatech Diagnostics. “Leica will bring global brand recognition, worldwide commercial reach, extensive cytogenetics and histology portfolios, and the automation of diagnostic tests on well-established systems. This will tremendously increase the number of customers that can benefit from Kreatech’s superior solutions.”

Related Links:
Leica Biosystems
Kreatech Diagnostics


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Staining System
RAL DIFF-QUIK
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.